FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

Silligion, D.C. 20049	

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burd	en							
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Khuong Chau Quang  (Last) (First) (Middle)  C/O PIERIS PHARMACEUTICALS, INC.					2. Issuer Name and Ticker or Trading Symbol PIERIS PHARMACEUTICALS, INC. [ PIRS ]  3. Date of Earliest Transaction (Month/Day/Year) 01/25/2017						RS Che	Relationship of Reporting Person(s) to Issuer neck all applicable)  X Director X 10% Owner  Officer (give title below) Other (specify below)					
255 STATE STREET, 9TH FLOOR  (Street)  BOSTON MA 02109  (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	Individual or Joint/Group Filing (Check Applicable Line)      X Form filed by One Reporting Person     Form filed by More than One Reporting Person					
1. Title of Security (Instr. 3) 2. Tran				ransactio	active Securities Acq action 24. Deemed Execution Date, if any (Month/Day/Year)			3. Transaction Code (Instr	4. Securiti	f, or Beneficially les Acquired (A) or Of (D) (Instr. 3, 4 and  (A) or (D) Price		5. Amoun Securities Beneficia Owned Fo Reported Transactio	5. Amount of 6. C Securities For Beneficially (D) Owned Following (I) (		Direct Indirect I	7. Nature of ndirect Beneficial Dwnership Instr. 4)	
Derivative   Conversion   Date		3. Transaction	(e.g., p						ired, Disposed of, or Benefici options, convertible securities  6. Date Exercisable and Expiration Date (Month/Day/Year)  7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported	e Ownersh s Form: Direct (D) or Indirect g (I) (Instr.	Ownership	Beneficial Ownership t (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transacti (Instr. 4)	on(s)			
Stock Option (right to buy) <sup>(1)</sup>	\$2.01	01/25/2017		A		10,313 <sup>(2)</sup>		01/25/2017	01/25/2027	Common Stock	10,313	\$0.00	10,31	3	D		
Stock Option (right to buy)	\$2.01	01/25/2017		A		20,000		(3)	01/25/2027	Common Stock	20,000	\$0.00	20,00	0	D		

## **Explanation of Responses:**

- 1. The Reporting Person is an employee of OrbiMed Advisors LLC ("Advisors") and is obligated to transfer any shares issued under equity grants made to him by the Issuer, or the economic benefits thereof, to Advisors for the ultimate benefit of OrbiMed Private Investments III, LP and OrbiMed Associates III, LP.
- 2. The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan
- $3. \ The stock option will vest in four equal installments on each of March 31, June 30, September 30, and December 31, 2017.$

## Remarks:

/s/ Marc D. Mantell, Attorneyin-fact 01/3

01/30/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.